PacBio, once slat­ed to be ac­quired by Il­lu­mi­na, is tak­ing on the DNA gi­ant

Pa­cif­ic Bio­sciences, a com­pa­ny that Il­lu­mi­na once tried to buy, is com­ing for its for­mer suit­or.

More than three years ago, the com­pa­nies called off their $1.2 bil­lion merg­er af­ter an­titrust op­po­si­tion. Back then, Pa­cif­ic Bio­sciences, known as PacBio, was in a fi­nan­cial­ly pre­car­i­ous po­si­tion but is now pos­ing a com­pet­i­tive threat to Il­lu­mi­na.

PacBio is cap­i­tal­iz­ing on the de­mand for read­ing longer pieces of DNA, while ex­pand­ing in­to a mar­ket dom­i­nat­ed by Il­lu­mi­na. At the same time, Il­lu­mi­na finds it­self with slow­ing sales, an in­ter­im CEO and an­oth­er ac­qui­si­tion that could be tor­pe­doed be­cause of an­titrust reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER